Approved Ligands

lusutrombopag.

LX-4211 is a potent dual SGLT2/1 inhibitor: Antidiabetic agents.

LX-4211 is a potent dual SGLT2/1 inhibitor: Antidiabetic agents.

LX-4211 is a potent dual SGLT2/1 inhibitor: Antidiabetic agents.

LX-4211 is a potent dual SGLT2/1 inhibitor: Antidiabetic agents.

LX-4211 is a potent dual SGLT2/1 inhibitor: Antidiabetic agents.

LX-4211 is a potent dual SGLT2/1 inhibitor: Antidiabetic agents.

Macitentan is an orally active, non-peptide, dual ETA/ETB (endothelin) receptor antagonist with IC50 of 0.5 nM/391 nM.

Macitentan is an orally active, non-peptide, dual ETA/ETB (endothelin) receptor antagonist with IC50 of 0.5 nM/391 nM.

Macitentan is an orally active, non-peptide, dual ETA/ETB (endothelin) receptor antagonist with IC50 of 0.5 nM/391 nM.

Maraviroc has been used as a C-C chemokine receptor type 5 (CCR5-specific) inhibitor in murine monocyte/macrophage cell line J774A.1, porcine uterine luminal epithelial cells and human lung CD4+ T cells.

Maraviroc has been used as a C-C chemokine receptor type 5 (CCR5-specific) inhibitor in murine monocyte/macrophage cell line J774A.1, porcine uterine luminal epithelial cells and human lung CD4+ T cells.